Indaptus Therapeutics, Inc. is a biotechnology company developing novel cancer immunotherapy treatments for patients with unresectable or metastatic solid tumors and lymphomas through its subsidiaries Decoy Biosystems and Intec Pharma Ltd. The company has not yet generated revenue from product sales and funds its operations through equity financing and capital raises from investors. The company incurs substantial research and development expenses, primarily directed toward clinical trials and contract research organizations, as well as general and administrative costs, with operations funded by a combination of direct equity investments and debt instruments until it can secure additional financing or pursue strategic growth opportunities.